News >

Arsenal of Targeted Therapies Slated to Expand in NSCLC

Caroline Seymour
Published: Thursday, Aug 15, 2019

Badi El-Osta, MD, an assistant professor in the Department of Hematology and Medical Oncology at Winship Cancer Institute, Emory University School of Medicine

Badi El-Osta, MD

Next-generation sequencing is recommended for patients with advanced non–small cell lung cancer (NSCLC) irrespective of smoking status, as there are several emerging agents for patients who harbor historically difficult-to-target alterations.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Publication Bottom Border
Border Publication
x